The crowdfunding campaign initiated by the Universitat Jaume I this academic year 2022-2023 and aimed at obtaining donations for scholarships and research projects in the social field, has exceeded the amount of €25,000 with more than 160 individual donations.
Read more on the subject and find the latest finance news of the day with the born2Invets mobile app.
Among the entities that have donated to the campaign is the company BECSA, which has joined as a sponsor with €3,000
This campaign of fundraising through crowdfunding, under the slogan “You also add up, become a donor!” is promoting the collaboration of the university community and all citizens to obtain sufficient resources to strengthen the Scholarship Fund of the UJI and to expand the lines of work in three research projects related to cancer and Alzheimer’s, two diseases that significantly affect our society.
The first part of the campaign, the active phase, will end this February, and the resources raised up to that point will be allocated to the projects that have obtained them to begin their management. From March until the end of this academic year, the passive phase will begin, where the four projects will continue to be active on the UJI donation platform, www.donacions.uji.es, in case any individual or legal entity still wants to collaborate with any of these university projects.
The four projects that are part of the crowdfunding campaign are:
The UJI Scholarship Fund, which aims to obtain sufficient resources to meet the needs of students with financial problems or unexpected situations to continue their university studies.
The Physical Activity and Oncology project, which aims to expand research focused on the ability to modulate and mitigate the side effects of cancer treatments through specialized physical exercise programs.
The “Biotechnology against Alzheimer’s disease” project, which aims to contribute to the understanding of the underlying causes of neuronal death in order to provide new molecular targets for the design of effective treatments against Alzheimer’s disease using biotechnological tools.
The skin cancer prevention project, which seeks to analyze the genetic and environmental factors involved in the appearance of skin lesions, as well as the molecular mechanisms involved in the formation and progression of skin cancers.
Individuals or legal entities contributing to the donation campaign may benefit from tax deductions, depending on the contribution made.
In the case of individuals who pay personal income tax (IRPF), 80% of the donation can be deducted from their taxable income if the contribution is equal to or less than €150 or, in the event that it is higher, the deduction will be 80% of the first €150 and 35% of the rest of the money contributed.
In addition, a 20% deduction can also be made on the regional section of the IRPF, since the four projects of the campaign have been declared scientific activities of social interest by the Generalitat Valenciana (Valencian Regional Government).
Therefore, an individual who makes a donation of €150 to the campaign, for example, will be able to deduct the full amount of the contribution made.
For sponsoring or collaborating companies that make a donation, such as the one made by the company BECSA, the tax deduction percentages vary between 35% and 40%, depending on the previous collaboration between the UJI and the collaborating entity.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in ACTUALITAT VALENCIANA, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval
Jazz Pharmaceuticals is a biopharmaceutical company dedicated to the development of drugs in neuroscience and oncology. Founded in 2003 in...
Citi Announced a $6 Million Loan to Sempli for SME financing
The credit granted by Citi was given in partnership with high-impact investors and multilateral development organizations. They all seek to...
How Will the Price of Ripple and Cardano Develop in the Next Few Days
The BOLL indicator shows no specific pattern and denotes the support price of $0.4969 and the resistance price of $0.5059,...
RADEEF: a 182 Million Dirham Plan to Combat Flooding in Morocco
RADEEF is also planning major expansion projects. Firstly, it plans to launch work on extending the wastewater treatment plant. The...
How Institutional Investors Feel About Impact Investing
Investors continue to face greenwashing when implementing impact investing. Among their key concerns are misleading or exaggerated impact claims (60%),...
Biotech2 weeks ago
Murcia Puts Out to Tender for €500,000 the Works of the Clinical Trials Unit in Arrixaca
Africa6 days ago
Immorente Invest Maintains its Financial Stability
Biotech2 weeks ago
Asabys Partners Leads a €14 Million Round in Gradient Denervation
Crowdfunding2 days ago
GoodNews Launches a Crowdfunding Campaign on Crowdcube